
- /
- Supported exchanges
- / US
- / PLRX.NASDAQ
Pliant Therapeutics Inc (PLRX NASDAQ) stock market data APIs
Pliant Therapeutics Inc Financial Data Overview
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pliant Therapeutics Inc data using free add-ons & libraries
Get Pliant Therapeutics Inc Fundamental Data
Pliant Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -232 848 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.7469
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pliant Therapeutics Inc News

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical ...


Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activi...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such invest...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such invest...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.